• Iterata AG

    real world medical data analysis

  • Scanning for Search & View

    We digitise and automate your business processes.
    The digitised information is immediately searchable
    and available to all authorised persons.

  • Rare Diseases

    Cohort Finding across multicenter for patients with rare diseases
    Direct patient identification from routine clinical practice
    Search profiles for characterization and support for rare diagnoses
    Fast and simple result extraction for the rare diseases registers

  • Launch of Personalized Medicine using the example of Pharmacogenetics

    A comprehensive pharmacogenetic overall analysis of the blood or saliva sample enables personalised drug optimisation including drug interaction analysis based on the individual genotype.

  • Creating Value for Patients

    Outcomes are the core target of medical diagnostics and therapies

    Which data do we rely on?

    How can we operationalize our data to ask and answer decisive questions about outcomes?

  • Life Saving

    Near real-time escalation & notification for critical or pathological information

    Speed up on clinical decision support (point of care)

  • Searchability

    Finding relevant information in real-time


    We reduce interfaces dramatically

    Speed Technology

    Access to relevant information and computational knowledge in near-real time for Domain & Business Owner

we just observe the data
we do not copy


Finding relevant information fast - linking of clinical data, laboratory data and genetic data

Digitalization of Patient Dossier and automation of your Processes

Scanning for Search & View

A classic manual archive of patient documents in paper form takes up space, is costly to operate and can only be viewed by stakeholders to a limited extent. The Iterata solution "Scanning for Search & View" immediately creates space that can be used for other purposes and makes the scanned patient documents machine-readable through OCR (Optical Character Recognition) for automated assignment to the patient dossier. The digitized information is immediately searchable and available to all authorized persons. Predefined evaluations and ad-hoc analyses can be immediately extracted from the data in the form of reports and tables.
For the introduction of a scanning solution in a healthcare organization, the focus is on the simple connection of physical and electronic documents to a patient dossier. Our goal is to simplify and automate your process and eliminate unnecessary interfaces. As a unique feature, the system is based on the complete searchability of digital documents (unstructured and structured data) on Iterata's Swiss Digital Health Platform (SDHP).
The search capabilities allow quality checks, migrations, and linking of your data with other medical and administrative content. As a Digital Health Consortium, we see ourselves as an enabler. Along the phases of access, know-how, new business models, transformation, process efficiencies, education, research and publication, we accompany you as a partner and technology supplier in clinical implementation and digitalization.

Your benefits and advantages, project planning, modules and price indication

Structured Data Entry

Structured Data Entry (SDE) is a basic prerequisite for an improved decision-making process. Data quality increases, the process is accelerated and costs are optimised. In addition, daily medical practice and research is facilitated by a standardised, clearly formulated and consistent catalogue of questions. If the data entry is structured, the data can be evaluated in real time and there are no longer delays in report generation. The data becomes addressable and therefore searchable and is permanently monitored. Iterata has developed a solution that allows professionals to define their structures (items) in corresponding lists, trees up to graphs and thus automatically generate their application for data capture in the field of clinical workflow. This allows clinicians to create intelligent applications and forms, including the automatic generation of reports. This tool enables to create personalised and clinician-tailored applications and to build and expand domain knowledge and the corresponding notions of data structures and entities.

Structured Data Entry - comming soon
Link will be provided: Your benefits and advantages with Structured Data Entry

Factsheet Structured Data Entry

Diagnostic Profiles and Monitoring

  • Diagnostic Search Profiles - comming soon


  • Life Saving Apps for Laboratories and Clinics (e.g. Cardiology)
  • Speed Apps for clinical decision support
  • Escalation & Notification Application for critical or pathological lab value
  • Screening of high risk patients through search profiles & algorithms


  • Increase your Master Data Quality
  • Curate your Data, Outcomes and Results
  • Data protection Solutions based on GDPR guidelines

Focus: Health Care Organizations, Hospitals, Clinics

Showcase - Laboratory and Patient Information System

Our customer, a Swiss based hospital holds decades of laboratory results and clinical reports. Although these documents are available in electronic form, they could not easily be searched and accessed.

In our project, we extracted these documents into a structured format and built fully electronic patient dossiers. This enables our customer to execute anonymized clinical research with unprecedented cohort sizes (thousands of patients rather than hundreds) and excelent quality of data. As a side effect, operations can access patient data much faster which saves administrative costs.

Research & Quality Control

Iterata enables medical researchers across Swiss hospitals to identify patient cohorts without exchanging the sensitive patient dossiers.

For compliance with the requirements of the Ethics Commission and the Human Research Act, a strict separation of the data & results is required

Cohort formation from medical data within hospitals or across mutiple hospitals.
• Level 1: Availability of patients
• Level 2: Number of patients & groups
• Level 3: Question focused data set (QFD)
• Level 4: Complete QFD for research study matched and agreed by patient

Calls & Grants:

2020 EU-Horizon: INnovative Platform for Data Collection, Retrieval and Evaluation in Digital Diagnostics and ReSEarch (INCREASE).

2018 SPHN: Winner of Swiss Personalized Health Network SPHN-GRANT
SPHN: Clinical research from multi-modality data sources
Project SPHN

2013 SystemsX: CliNETx Scientific Information
CliNETx Summary

Iterata Health Platform based on 2-Speed IT

The 2-Speed approach enables research and innovation to be driven directly from the operation

• Search engine access and analysis of real world medical data feasible
• Identification and evaluation of cases for clinical and study purposes possible
• Real world data analysis of adverse drug effects in sense of “intelligent assistance”
• Expansion over different databases of several hospitals imminent

Focus: Clinicians, Physicians, Family Doctors, Scientists

Launch of Personalized Medicine using the example of Pharmacogenetics

A comprehensive pharmacogenetic overall analysis of the blood or saliva sample enables personalised drug optimisation including drug interaction analysis based on the individual genotype.

From a comprehensive perspective, the Swiss Digital Health Platform (SDHP) is a unifying platform that integrates key healthcare stakeholders to significantly improve treatment and prophylaxis options. At the heart of the SDHP platform is the ability to perform high quality genetic analyses and provide high quality decision support for physicians and patients based on the sequenced data. In order to achieve a higher informative value, gene analyses should not be considered in isolation, but should be assessed in combination with other available patient data (such as diagnoses, laboratory values and treatment findings). In this way, patient data becomes the essence of the SDHP platform. Gene sequencing thus becomes a crystallization point for individual patient dossiers, which can be enriched with many other data, even independently of a direct medical need. Within the framework of defined activities and processes, authorized actors in designated roles can use data from these data via corresponding services.

Salient features

Extraction of salient features from clinical data

Questions for quality assurance

• How effective are drugs in real life?
• How frequent are undesired effects of drugs in routine care?
• Are potential serious drug interactions considered in routine care prescription?
• Which sequence and dosing of drugs is optimal for outcome?

Questions for clinical studies

• Which cases with a given (rare) diagnosis are cared for in my unit?
• Which patients fulfil a given set of classification/ diagnosis criteria?
• Can patients be ranked according to activity and response to treatment?
• Are data from routine care superior to those of randomised, prospective clinical trials?

Focus: Clinicians, Physicians, Laboratory, Diagnostics and Pharmaceutical Companies

About Iterata

We foster health operations and research in collaboration with hospitals, clinics, the pharmaceutical & laboratory industries and educational institutions through technological know-how, expertise and capacity

Iterata applies an innovative technological approach to the searchability and structuring of large, complex, unstructured data sets from the clinical routine

We enable interoperability between systems and organizations and exchange of nationwide routine clinical data that becomes accessible for research

Search Technologies

We provide access to state-of-the-art Search Technologies.

Algorithms -> Data

We do not move data; we send our algorithms to the data. Data remains in its secure policy space.

Data addressability

We reduce interfaces dramatically.

Data Security

We ensure highest level data security through secure transmission technology, encryption and automated anonymization/depersonalization.

We create the pre-requisite for high quality clinical routine & research

Our tools allow to create a structured data environment from multi-stakeholder environment with an inhomogeneous data landscape. Full de-personalisation/anonymization is guaranteed. The integration of key stakeholders allows to combine diagnostic and clinical data which over time do provide access to a vast pool of relevant data for research.

Our tools sweep over the existing data landscape without copying and organize data in a highly structured way - the Iterata Business Intelligence tools do not require a change of the underlying IT landscape – data stays in its policy spaces.

The tool is pre-destined to include the further commoditizing Genetics and combine it with diagnostic and clinical data to build the fundament for genotyping based treatment. There are benefits in the operations, as the structured data allows to create a Speed Layer for fast decision making for the involved GPs and the clinicians


We are a dedicated team with unique skills and experience.

Stefan Hubeli


Stefan Hubeli is the CEO of Iterata AG – Medical Services, specialized on massive data platforms, new Search Technologies, algorithmic and continuous delivery approaches based on two speed IT architectures in healthcare. Before joining Iterata, Stefan Hubeli was a Senior Manager at Credit Suisse Group AG for the past 13 years, where he became the Head of Trade Finance and Syndication Businesses. He worked directly for the CEO Private and Business Banking in terms of value creation and excellence projects (lean sigma), as well as on strategic organizational and growth initiatives for the Chairman Office. He was in charge of the development of the Credit Suisse Strategy China for Corporate & Institutional Banking. This included the setup and implementation of the full business range with processes in Corporate Finance, Aviation Finance, Ship Finance, Trade Finance, Export Finance, M&A, IPOs, as well as the Financial Institution Services and Private Banking Business. Therefore, he spent two years in Beijing, New York and Washington D.C. Stefan Hubeli studied Computer Science at University of Applied Science Nordwestschweiz and Economics at the University of Hagen. In the meantime, he was also Associate Lecturer at the University of Applied Science Aargau in the Department Technology and Economics.

Fabian Stierli


Fabian Stierli is VP Group Strategy and M&A for Barry Callebaut AG, the leading manufacturer of chocolate and cocoa products with a global market share of 25%. In his role he reports directly to the Group CEO to lead the Group’s global strategic development and change projects. Barry Callebaut ranks among Switzerland’s top 50 companies. Prior to joining Barry Callebaut AG, Fabian Stierli was a Senior Investment Manager at Jacobs Holding AG. In this capacity, he worked closely with the portfolio companies’ management teams on strategic, organizational and operational initiatives. He also developed and assessed investment strategies for Jacobs Holding AG. Fabian Stierli kick-started his career with Bain & Company, where he led projects on strategy and organization development mainly for industrial goods, consumer goods, utilities and healthcare clients. He also advised private equity clients on the buy-side. As a Principal he was part of Bain’s leadership team in Zurich. Before Bain, Fabian Stierli gained experience with Bühler AG and as an entrepreneur. Fabian Stierli is a founding member and shareholder of Iterata AG and serves as its Chairman of the Board of Directors. He holds a Master’s degree in Food Engineering from the Federal Institute of Technology in Zurich ETHZ and a MBA from INSEAD.

Prof. em. Alan Tyndall

Member of the Board

Alan Tyndall was appointed professor and head of the Department of Rheumatology at the University of Basel in 1991. His main interests are stem cell therapy of autoimmune diseases and systemic sclerosis (scleroderma). He has participated in the working party of the ESF sponsored study of investigator initiated trials and the EMA study group regarding third country clinical trials. Alan has served on the boards of the EBMT and EULAR and was a founding member and secretary of the EU-LAR Scleroderma Trials and Research (EUSTAR) group as well as the World Scleroderma Foundation (based in Basel). He is chairman of the safety committees of two NIH sponsored stem cell trials, is an emeritus professor at the University of Basel and a board member and co-founder of the bioinformatics company Iterata AG and Magenta Therapeutics. Alan has published over 230 peer reviewed papers, 100 of which relate to stem cell ther-apy and 30 book chapters. Alan received his undergraduate medical degree at the University of Sydney in 1972. His post graduate qualifications are FRACP, FRCP(Ed), with post graduate experience in Canberra, Sydney and London.

Iterata Medical Services is a Swiss based company specialized in the development of agile and incremental business & software processes. Our competence derives from the experience of our advisor network & partners: In response to market and customer alignment needs, we launched Iterata Medical Services in 2014 relying on general market solutions for clinical operations and research. We provide data driven solutions with strong orientation on the clinical routine and research requirements. We enable business domain owners (clinicians, researchers, pathologists, immunologists, geneticists, etc.) to make patient, general practitioner and supplier data visible in a fast way.


Are you ready to start your business project? Give us a call or drop us a line.

Visit us

Iterata AG - Medical Services
Industriestrasse 8
CH-5722 Gränichen

Send a mail


Call us

+41 62 842 88 27


Click here